Labeling efficiency of Tb3+ conjugated CD133 monoclonal antibody nanocomplex targeting in vitro metastatic cancer cells

Le Nhat Minh, Vo Trong Nhan, Tran Thu Huong, Nguyen Thi Nga, Le Tri Vien, Phung Thi Kim Hue
Author affiliations


  • Le Nhat Minh
  • Vo Trong Nhan
  • Tran Thu Huong
  • Nguyen Thi Nga
  • Le Tri Vien
  • Phung Thi Kim Hue



Cancer stem cells, CD133 monoclonal antibody, ET2-luminescent nanocomplex, HEK-293, Ion Tb3 , NTERA-2


Efficient cancer treatment remains a huge challenge worldwide. As reported by the World Health
Organization, the number of cancer patients is estimated to be 24 million in 2035, which is a 70% increase
compared to 14.1 million in 2012. The severity of cancer is due to the presence of cancer stem cells (CSCs),
which are directly related to drug resistance, metastasis, and tumor relapse. Because of the unknown location of
the primary tumor and/or the residency of CSCs, standard therapies deliver a high dose of drugs to the whole body,
which can have negative effects and deadly consequences for patients undergoing treatment. Therefore, efficient
luminescent materials for labeling and tracking CSCs are urgently needed to determine their distribution and
target treatment. Herein, a fluorescent Tb3+ nano-ion and CD133 monoclonal antibody (mAb) were conjugated
into a nano probe-complex (ET2). Tb3+ nano-ion is a rare-earth element and the CD133 mAb targets CD133,
which is a CSC surface marker. The Tb3+ nanorods were surface treated with silica and activated with -NH2 for
functioning before being coupled with CD133 mAb. Strong fluorescent Tb3+ nanorods were used to decrease the
toxicity of high-dose medicines, and the purpose of the CD133 mAb was to increase the specific binding capacity
of CSCs to the ET2 nanocomplex. The luminescent properties of this coupled ET2 complex were determined
and its ability to target and label CSCs was determined using the pluripotent human embryonic carcinoma cell
line, NTERA-2. Fluorescence microscopy showed strong luminescent signals from ET2-exposed NTERA-2
cells. It was also demonstrated that the ET2 nanocomplex effectively labeled up to 97.74% of the tested NTERA-
2 cells, but only 2.35% of CCD-18Co human colon normal cells. Therefore, these results show that the ET2
luminescent nanocomplex specifically targeted and labeled CSCs, and may be used for further applications in
fundamental and clinical research.


Download data is not yet available.


. Calvet C.Y., André F.M., Mir L.M. (2014), "The culture of cancer cell lines as tumorspheres does not systematically result in cancer stem cell enrichment", PLoS One, 9(2), e89644.

. Clevers H. (2011), "The cancer stem cell: premises, promises and challenges", Nature medicine, 17(3), 313.

. Gil J., Stembalska A., Pesz K.A., Sasiadek M.M. (2008), "Cancer stem cells: the theory and perspectives in cancer therapy", Journal of Applied Genetics, 49(2), 193-199.

. Vinogradov S., Wei X. (2012), "Cancer stem cells and drug resistance: the potential of nanomedicine", Nanomedicine, 7(4), 597-615.

. Hương T.T., Anh T.K., Khuyên H.T., Tuyên L.Đ., Lộc Đ.X., Đạt T.N., Tú V.Đ., Vinh L.T., Minh L.Q. (2012), "Nghiên cứu tính chất quang của các thanh nano chứa ion đất hiếm Tb3+ và Eu3+ nhằm ứng dụng đánh dấu huỳnh quang y sinh", Tạp chí Khoa học và Công nghệ, 50(1A), 126-132.

. Arap W., Pasqualini R., Montalti M., Petrizza L., Prodi L., Rampazzo E., Zaccheroni N., Marchiò S. (2015),“Luminescent Silica Nanoparticles for cancer diagnosis”, Current medicinal chemistry, 20(17), 2195-2211.

. Asha S., Ananth A.N., Vanitha kumari G., Prakash B., Jose S.P., Rajan M.A.J. (2017), “Biocompatible fluorescent nano-apatite with ionic silver- Its antibacterial activity and cytotoxicity towards cancer cells”, Materials Today: Proceedings, 4(2), 4309-4318.

. Nhân T.V, Minh N.L., Đỗ T.T., Hương T.T., Phùng T.K.H. (2019), “Đánh giá khả năng phát hiện tế bào ung thư ruột kết (HT-29) của vật liệu nano chứa ion đất hiếm Tb3+”, Tạp chí Công nghệ Sinh học, X(X): XX-XX (đã chấp nhận đăng, đang trong quá trình in ấn).

.Chen J., Liu Q., Xiao J., Du J. (2015), "EpCAM-Antibody-Labeled Noncytotoxic Polymer Vesicles for Cancer Stem Cells-Targeted Delivery of Anticancer Drug and siRNA", Biomacromolecules, 16(6), 1695-1705.

. Lu V. M., Crawshay-Williams F., White B., Elliot A., Hill M.A., Townley H.E. (2019), "Cytotoxicity, dose-enhancement and radiosensitization of glioblastoma cells with rare earth nanoparticles", Artificial Cells, Nanomedicine, and Biotechnology, 47(1), 132–143.




How to Cite

Nhat Minh, L., Trong Nhan, V., Thu Huong, T., Thi Nga, N., Tri Vien, L., & Thi Kim Hue, P. (2020). Labeling efficiency of Tb3+ conjugated CD133 monoclonal antibody nanocomplex targeting in vitro metastatic cancer cells. Vietnam Journal of Biotechnology, 17(3), 435–440.




Most read articles by the same author(s)